Galactosemia Clinical Trials and Treatments

Galactosemia is caused by deficiency of the enzyme galactose-1-phosphate uridyltransferase (GALT), leading to accumulation of galactose-1-phosphate in red blood cells, white blood cells, and other tissues where it causes cellular damage through osmotic stress and toxic effects on cellular metabolism. Classical galactosemia (GALT deficiency) is the most severe form. Manifestations appear within days to weeks after birth in fed infants: cataracts develop as galactose is shunted into the aldose reductase pathway, producing galactitol which accumulates in the lens causing osmotic stress and lens opacification ("oil drop" cataracts visible in first week of life).

The most common symptoms of Galactosemia include Cataracts developing in first days to weeks, Feeding difficulty and poor weight gain, Vomiting and diarrhea, Jaundice and hepatomegaly, Intellectual disability if untreated, among others. Classical galactosemia 1 in 30,000 to 60,000 people; variant forms more common. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Galactosemia from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Early diagnosis via newborn screening enables immediate galactose (lactose) restriction, which effectively prevents cataracts, acute liver disease, intellectual disability, and other acute manifestations. Lactose-free infant formula (typically soy-based or hydrolyzed protein formula) must be substituted immediately upon diagnosis, before first breastfeeding if possible.

As of September 2026, Trial Friend's curated drug index does not include an FDA-approved treatment specific to Galactosemia. The Treatments section of this page checks FDA drug labels live and lists any approved drug whose label names the condition, and the trials listed below cover the investigational options.

Galactosemia is caused by variants in the GALT, GALK1 and GALE genes. Classic galactosemia is GALT; the Duarte GALT variant causes a much milder form.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child. Classical galactosemia 1 in 30,000 to 60,000 people; variant forms more common. Genetic testing confirms the diagnosis.

Yes. Genetic testing for Galactosemia looks at the GALT, GALK1 and GALE genes. Classic galactosemia is GALT; the Duarte GALT variant causes a much milder form.

It is inherited in an autosomal recessive pattern: both parents are usually unaffected carriers, and each pregnancy has a 1 in 4 chance of an affected child.

A confirmed variant establishes the diagnosis and is often required to enroll in gene-specific trials. The labs currently offering the test are listed in the Genetic Testing section of this page, pulled live from the NIH Genetic Testing Registry. A genetic counselor can help interpret the result and decide which relatives should be tested.

Eligibility for Galactosemia clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Galactosemia clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.